Clinical Trial Update: A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a single intramuscular dose of motavizumab for RSV illness in young children; trial terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Motavizumab (motavizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Participants Less Than 12 Months of Age With RSV Illness | Phase 2 | Status: TERMINATED | Results posted: 2021-08-17